The characteristics of HIV patients who are long-term responders to nevirapine by Tenneti, Vijay Seshadri
\ 
School of Pharmacy 
The Characteristics of HIV Patients Who are Long-Term 
Responders to Nevirapine. 
Vijay Seshadri Tenneti 
This thesis is presented for the degree of 
Master of Pharmacy 
of 
Curtin University of Technology 
September 2007 
Curtin University Library 
 i 
Declaration 
 
This Thesis contains no material which has been accepted for the award of any other 
degree or diploma in any other University or institute. 
 
To best of my knowledge and belief this thesis contains no material previously published 
by any other person except where due acknowledgement has been given. 
 
 
Signature: ……………………….. 
 
(Vijay Seshadri Tenneti) 
 
Dated: 
 
 
 
 ii 
Abstract 
Objective: To define Nevirapine long term responders (NLTRs) and identify the 
characteristics of patients who stay on the drug for long periods of time without adverse 
effects and maintain suppression of HIV replication without development of resistance. 
 
Methodology: Demographic and clinical data was collected for all the patients >18 years 
old from Department of Clinical Immunology, Royal Perth Hospital, Western Australia.  
All the patients included in the study received Nevirapine as part of their first regimen of 
anti-retroviral therapy. Data collection and analysis were divided in three groups based 
on their length of stay on Nevirapine; short-term, medium and long-term responders.  
Patients who stayed on Nevirapine continuously for more than five years were considered 
long-term responders (60+ months). Patients who withdraw before six months of therapy 
due to the drug’s side effects or any other reason are considered short-term responders (0-
6 months). Patients whose length of stay on the drug is intermediate between these two 
groups are considered as medium responders (6-60 months).  Investigation of the possible 
genetic influence on response to Nevirapine was made by analysis of genetic markers like 
HLA-B35+C4, HLA-DR1, and HLA-B14.  
 
Results: We found no difference in the frequencies of HLA-DR1 or HLA- B14 in the 
three groups. However, we found that HLA-B35+HLA-C4 did not occur in any of the 
Nevirapine long term responders (NLTRs).This was not described in previous studies. 
Furthermore, when a survival analysis was performed, carriage of HLA-B35+HLA-C4 
identified patients who were not NLTRs. 
 
Conclusion: This study was carried out to determine whether or not factors like age, 
gender, baseline CD4+ count, baseline RNA, and HLA alleles would predict the length of 
stay on Nevirapine. Although the factors considered for the study have previously been 
associated with hyper-sensitivity reactions, they do not predict how long a patient would 
stay on the drug. However, it can be understood from the study that patients who had a 
combination of HLA alleles B35+HLA-C4 would not continue on Nevirapine use for a 
prolonged time. 
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1 Introduction 
1.1 Human Immunodeficiency Virus 
Human Immunodeficiency virus (HIV) belongs to the lenti virus subclass of retroviruses. 
As with all viruses HIV cannot reproduce on its own and so must infect cells of a living 
organism in order to replicate1. HIV preferentially infects CD4 T- cells causing immune 
activation, which results in CD4 T-cell dysfunction and depletion. This effect on the 
immune system results in the development of an immunodeficiency syndrome known as 
Acquired Immuno Deficiency Syndrome (AIDS). This manifests as a persistent failure of 
immune cell function over time and intrusion by several different opportunistic agents, 
the result of which is loss of the ability of the body to fight infection and the subsequent 
acquisition of diseases. HIV was formerly defined as a non curable infection leading to 
death from one or more opportunistic infections. In recent times increasing arrays of 
effective antiretroviral drugs have become available. 
 
1.1.1 HIV and AIDS in the World 
Since AIDS was first recognised in the early 1980s, HIV/AIDS has emerged as one of the 
largest global threats to development and the economic and social stability of developing 
countries. HIV/AIDS is a global emergency. Already 20 million people, the equivalent of 
Australia’s population, have died as a result of the pandemic and another 38 million 
currently live with the virus. Around 7.4 million people are living with HIV/AIDS in the 
Asia-pacific region alone. HIV/AIDS impacts on every level of society. It is one of the 
greatest threats to the economic and social development, stability, and security of 
developing countries2. 
 
The United Nations releases new estimates of the number of people living with HIV 
infection every year (Table 1-1 and Table 1-2). The number of people affected with the 
disease continues to rise in spite of the efforts to prevent worldwide HIV infection.  
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Table 1-1 HIV in World Population3 
Number of people living 
with HIV in 2005 
Total 40.3 million (36.7-45.3 
million) 
 Adults 38.8 million (34.5-42.6 
million) 
 Women  17.5 million (16.2-19.3 
million) 
 Children under 15 years 2.3 million  (2.1-2.8 
million) 
People newly infected with 
HIV in 2005 
Total 4.9 million (4.3-6.6 
million) 
 Adults 4.2 million (3.6-5.8 
million) 
 Children under 15 years 700 000 (630 000-820 
000) 
AIDS deaths in 2005 Total 3.1 million (2.8-3.6 
million) 
 Adults 2.6 million (2.3-2.9 
million) 
 Children under 15 years 570 000 (510 000- 670 
000) 
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Table 1-2 Global Estimates for Adults and Children, End 20053 
Regional HIV and AIDS statistics and features, 2003 and 2005 
 
Adults and 
children living 
with HIV 
Adults and 
children newly 
infected with 
HIV 
Adult 
prevalence (%) 
Adults and child 
deaths due to 
AIDS 
Sub-Saharan 
Africa 
2005 
2003 
 
 
25.8 million 
24.9 million 
 
 
3.2 million 
3.0 million 
 
 
7.2 million 
7.3 million 
 
 
2.4 million 
2.1 million 
North Africa 
and Middle 
East 
2005 
2003 
 
 
 
510000 
500000 
 
 
 
67000 
62000 
 
 
 
0.2 
0.2 
 
 
 
58000 
55000 
South and 
South-East 
Asia 
2005 
2003 
 
 
 
7.4 million 
6.5 million 
 
 
 
990000 
840000 
 
 
 
0.7 
0.6 
 
 
 
480000 
390000 
East Asia 
2005 
2003 
 
870000 
690000 
 
 
140000 
100000 
 
0.1 
0.1 
 
41000 
22000 
Oceania 
2005 
2003 
 
74000 
63000 
 
8200 
8900 
 
0.5 
0.4 
 
3600 
2000 
Latin America 
2005 
2003 
 
1.8 million 
1.6 million 
 
200000 
170000 
 
0.6 
0.6 
 
66000 
59000 
Caribbean 
2005 
2003 
 
300000 
300000 
 
30000 
29000 
 
1.6 
1.6 
 
24000 
24000 
Eastern Europe 
and Central 
Asia 
2005 
2003 
 
 
 
1.6 million 
1.2 million 
 
 
 
270000 
270000 
 
 
 
0.9 
0.7 
 
 
 
62000 
36000 
Western and 
Central Europe 
2005 
2003 
 
 
720000 
700000 
 
 
22000 
20000 
 
 
0.3 
0.3 
 
 
12000 
12000 
North America 
2005 
2003 
 
1.2 million 
1.1 million 
 
43000 
43000 
 
0.7 
0.7 
 
18000 
18000 
Total 
2005 
2003 
 
40.3 million 
37.5 million 
 
4.9 million 
4.6 million 
 
1.1 
1.1 
 
3.1 million 
2.8 million 
 
As per the WHO estimations, about 14000 new HIV infections occur worldwide every 
day and more than 95% of the infections are in the low and middle income counties. 
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Almost 2000 cases are children under 15 years of age and about 12000 are  people aged 
15-49 years of whom; almost 50% are women and 50% are 15-24 year olds. Barely about 
one in five HIV patients receive ARVs in the low- middle income countries4. Figure 1-1 
gives an overview of use of ARVs in the world. 
 
 
Figure 1-1 Use of ARV drugs  in the World4 
1.1.2 HIV in Australia 
Table 1-3 HIV infection in Australia3 
Estimated Population 20155000 
Population Growth Rate 1.1% 
Life Expectancy at birth Male= 83 years  Female= 78 years 
Number of people living with HIV 16000 ( 9700-27000) 
Adults aged 15-49 HIV prevalence rate 0.1% (<0.2%) 
Adults 15 and over living with HIV 16000 (9600-27000) 
Women aged 15 and over living with 
HIV <1000 (<2000) 
Death due to AIDS <500(<1000) 
Citizens from Australia accounted for major diagnosis for AIDS in the past decade.  
AIDS was diagnosed in 69% during 1996-2000 and 65.3% during 2001-2005 were 
among Australian born people. Figure 1-2 describes that there was no evidence of change 
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in rate of new acquired HIV infection in Australian Capital Territory, Western Australia, 
Tasmania and Northern Territory in the past ten years. However, there was an increase of 
20% and 40% in New South Wales and Victoria respectively during the same period of 
time5.  
 
 
Figure 1-2 Average annual incidence of diagnosis of HIV infection and AIDS, 2001-
2005, by State/Territory 5. 
 
1.1.3 Background information for the present study 
The development of antiretroviral therapy is the defining medical event in the 
management of patients with HIV infection that has occurred in the past two decades. 
Nevirapine a non-nucleoside reverse transcriptase inhibitor has shown confirmed efficacy 
in the treatment of HIV infection6. Licensed antiretroviral drugs have been developed 
rapidly in the last ten years doing miracles in the area of HIV/AIDS. It is estimated that 
Nevirapine therapy is an effective clinical and cost-effective option for HIV treatment 
compared to any other antiretroviral therapy7 . The high efficacy rate of Nevirapine is due 
to its wide distribution (readily crosses placenta and BBB) and low lipid profile qualities 
(increases serum lipids less than other ARVs). But due to Nevirapine induced toxicities; 
mainly hypersensitivity reactions like liver toxicity, skin rashes, flu like symptoms and 
fever which occur within the first 4-6 weeks of start of NVP therapy ; and development 
of resistance much later if the  advised treatment regimen is not adhered to, the long term 
use of the drug is under threat8. Nevirapine monotherapy suppresses HIV replication very 
effectively but resistance occurs rapidly and therefore, Nevirapine must be used in 
combination with other antiretroviral drugs9. Virological failure can occur due to: (a) 
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emergence of drug resistant virus (b) non adherence to therapy (c) interruptions to 
therapy10, 11. Despite good adherence some patients still experience virological failure, 
thus giving way to the thought that some other mechanisms are involved12 . However, 
some patients also remain on Nevirapine therapy for long periods of time. Studies have 
already been done to confirm that there exists an association between HLA, IL-1A and 
immunodeficient patients12. A research done by Price et al confirmed that alleles carried 
at IL1A-889 or IL1A+4845 may predict the control of HIV replication in already 
immunodeficient patients responding to HAART.  Some studies have supported that there 
exists an association between CCR5 and virological failure13. However, some studies 
oppose this theory stating that no such association occurs14, 15.  
 
This research aims to identify the characteristics of those patients who stayed on 
Nevirapine for long periods of time which may lead to the selection of people who might 
do well on the drug. This knowledge may allow a decision to be made whether 
Nevirapine should be administered to a patient based on their genetic profile and clinical 
characteristics, there by preventing unwanted complications of hepatitis or rash which 
might occur in patients treated with the drug. Hence in the present study genetic markers 
like HLA, IL-1A were used to investigate any association with response to Nevirapine 
therapy and HIV patients. 
1.1.4 HIV Structure 
Outside human cells HIV exists as uneven and globular particles; which are sometimes 
called virons. The surfaces of the particles are studded with numerous spikes (Figure 1-
3). They measure approximately 0.4 microns in diameter and can be viewed using an 
electron microscope16.  
 
 
 
 
1.1.5 HIV a Retrovirus 
Retroviruses have a double stranded RNA as their genetic material. They make a DNA 
copy of their RNA in order to replicate17. The DNA genes facilitate the process of 
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replication. An enzyme called reverse transcriptase facilitates this conversion. Once DNA 
is formed, it gets incorporated into human cells18. 
Lentivirus 
Lentiviruses or slow viruses are a class of viruses which are characterized by existing 
dormant for long periods of time after the initial stages of infection. They take a long 
time between initial infection and appearance of symptoms. Other viruses belonging to 
this class are SIV (Simian Immunodeficiency Virus)19 and FIV (Feline 
Immunodeficiency Virus)20. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3 Three-Dimensional Reconstruction of HIV Virions from Cryo-Electron 
Tomography 16 
A) A slice through the xy plane of a reconstructed tomogram from the −6-µm defocus 
dataset. The spike complexes are clearly visible on the viral surface. Some of the cores 
appear disrupted, reflecting AT-2 treatment. Scale bar represents 100 nm. 
(B) Surface rendering of one of the virions. The membrane is represented in blue, the 
core in red and the spikes in orange. 
(C) The same virus as in (B) viewed after removing half of the viral envelope along the 
dotted line to reveal the core.  
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HIV particles are encircled by two layers of coat made of fatty material called viral 
envelope or viral membrane. From this viral envelope project tiny spikes which are 
produced from proteins gp120 and gp4116, 21. These proteins are derived from viral pre-
protein gp 160 splicing. The layer immediately underneath viral envelope is called the 
matrix and is made from protein p16 (HIV matrix protein). The viral core or capsid is 
made from protein p24 and is generally bullet shaped (as shown in figure 1-4). The viral 
core also has a protein called p9 (the HIV nucleocapsid protein) that is not covalently 
joined to the viral RNA22. The three enzymes required for HIV replication are found 
inside the capsid. They are reverse transcriptase, integrase and protease. HIV’s genetic 
material, which consists of a pair of identical strands of RNA, is also held within the 
capsid. 
 
 
Figure 1-4 HIV viral proteins and gene structure17 
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1.1.6 Genetic Material 
Most viruses and almost all organisms store their genetic material on long strands of 
DNA. Retroviruses store their genetic information on two strands of RNA. HIV's 
replication process is comparatively more complicated than other viruses due to the 
presence of RNA. HIV has nine genes viz; gag, pol, env ( required to make structural 
proteins for new virus particles) tat, rev, nef, vif, vpr and vpu (code for proteins that 
control the ability of HIV to infect a cell, produce new copies of virus, or cause 
disease)17as described in Figure 1-4. A sequence called the long terminal repeat present at 
either end of each strand of RNA helps in controlling HIV replication (Figure 1-5). 
 
 Viral gene transcription is regulated by Tat and Rev and in due course useful for HIV 
replication. In vitro infection potential of HIV is increased by Vif gene as it associates 
with cytoskeletal elements17. Vpu gene plays its role by intervening in the assembly 
process whereas Vpr gene intervenes with the nuclear transport of viral genome. Nef is 
the gene with multiple functions including; down regulation of surface CD4 and MHC 
class I molecules, acceleration of clinical disease, modulation of signal transduction and 
ultimately favouring HIV entry into target cells by CD4 and chemokine dependant 
pathway23. A clear understanding can be obtained upon observing figure 1-5.  An outline 
of HIV gene products is illustrated in the Table 1-4 below. 
 
Table 1-4 HIV gene products17 
Structural proteins Regulatory proteins 
Viral envelope proteins: gp 41 
gp 120 
Transcription regulators: Tat 
Rev 
Core proteins: p 24 (Capsid) 
p 16 (matrix) 
p 9(nucleocapsid) 
Other proteins: Vif 
Vpu 
Vpr 
Nef 
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Figure 1-5 Schematic representation of HIV-1 and different RNA species 
Gag: group specific antigen, Gag-Pol: group specific antigen-polymerase, Env: envelope, 
Tat; trans-activator of transcription, Rev: regulator of expression of virion proteins, Nef: 
negative effector, Vif: virion infectivity factor, Vpr: viral protein r, Vpu: viral protein u, 
LTR; long terminal repeat 1. 
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Life Cycle and mechanism of Replication 
 
HIV replication can take place only inside human cells. The life cycle of HIV (Figure 1-
7) can be explained through the following steps; 
Step 1: HIV entry into human cells-  The process of infection begins when a HIV particle 
comes in contact with a human cell having a surface molecule called cluster designation 4 
(CD4)24-26. The cells which carry these molecules are called CD4 cells. Glycoprotein 
gp120 present in the viral envelope allows the virus to bind tightly to CD4 molecules. 
This binding causes a conformational change in the gp120 permitting it to bind to other 
molecules on the cell surface called the co-receptors. Later, the viral envelope fuses to the 
cell membrane, thus allowing the virus to enter the cell27, 28. Gp41 also present in the viral 
envelope plays a vital role in the fusion of virus to the cell (figure 1-7). Cell-to-cell 
spread of HIV also can occur through the CD4-mediated fusion of an infected cell with 
an uninfected cell.  
 
Step 2: Reverse Transcription- The replication of HIV is possible only after its genetic 
RNA is converted to DNA. Enzyme reverse transcriptase present inside the capsid helps 
in the conversion of viral RNA to viral DNA. Upon entry the HIV capsid releases viral 
RNA and viral protein in the cytoplasm where the RNA undergoes the process of reverse 
transcription and results in the formation of complementary DNA (cDNA) by the viral 
reverse transcriptase enzyme29. The enzyme reverse transcriptase incorporates an 
erroneous nucleotide at every 1500-4000 bases; this results in the emergence of 
mutations. This phenomenon underlies the development of drug resistant strains in 
patients receiving anti-retroviral drugs30.  
 
Step 3: Integration- The viral DNA which is newly formed enters the nucleus of the 
human cell. Viral cDNA undergoes a process of integration randomly with the host cell 
genome. This reaction would be catalysed here by the enzyme viral integrase which helps 
in joining the viral DNA with host DNA. At this stage the viral DNA is called provirus.   
    
 Step 4: Transcription- The provirus can produce new viruses only when RNA copies are 
prepared that can be read by the host cell’s protein-making machinery. These RNA 
copies are called messenger RNA (mRNA) and the process of production of mRNA is 
called transcription. Following integration, cellular transcription factors activate the viral 
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gene transcription thereby producing short and multiply sliced mRNA transcripts. These 
encode the regulatory proteins Tat, Rev and Nef. Tat acts by binding at the 5’ end of viral 
DNA sequence and enhances the process of transcription by 1000 fold31.  Rev links an 
RNA structure to the env gene region, thus causing the nuclear export of the incompletely 
spliced transcription units. HIV replication would get impaired significantly if the effects 
of Tat and Rev are inhibited32, 33.   
 
Step 5: Translation- HIV mRNA which is formed in the nucleus is now transferred to the 
cytoplasm. HIV proteins are critical to this process; for example, a protein encoded by the 
rev gene allows mRNA encoding HIV structural proteins to be transferred from the 
nucleus to the cytoplasm. Without the rev protein, structural proteins are not made. In the 
cytoplasm, the virus co-opts the cell’s protein-making machinery including structures 
called ribosomes to make long chains of viral proteins and enzymes, using HIV mRNA 
as a template. This process is called translation. Pre-proteins pr55 and Gag-Pol are 
formed during translation. Gag-Pol gets cleaved to produce viral enzymes like protease, 
integrase and reverse transcriptase.  
 
Step 6: Assembly and Budding- The mRNAs produce gp 160 which migrates to the cell 
membranes and is cleaved to form the regulatory proteins; VPr, Vpu, Vif and the 
envelope proteins gp 41 and gp 120. These HIV core proteins, enzymes and host 
membrane proteins are incorporated on the plasma membrane to form the viral envelope 
around the capsid which already contains the viral genomic RNA. The assembly process 
involves the utilisation of energy which is produced by unidentified cellular factors34.  
This immature viral particle buds off from the cell. At this stage of the viral life cycle, the 
core of the virus is immature and the virus is however not infectious. The viral enzyme 
protease cuts the long chains of proteins and enzymes that make up the immature viral 
core. Vpu induces CD4 degradation and causes the down-regulation of CD4 surface 
expression35.  During the budding pathway, binding between the HIV Gag protein and 
molecules in the cell directs the accumulation of HIV components in special intracellular 
sacs, called multi-vesicular bodies (MVB), which normally function to carry proteins out 
of the cell. In this way, HIV actively hitch-hikes out of the cell in the MVB by seizing 
control over normal cell machinery and mechanisms.  
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Figure 1-6 HIV entry through lymphocytes and monocytes by cognate recognition of 
viral glycoprotein 12017 
 
 
 
 
Figure 1-7 HIV replication with all the stages17 
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1.1.7 Pathogenesis of HIV disease 
 
A broad perspective of the complexities of HIV disease has been achieved36.  The clinical 
course of HIV infection comprises of the following stages: (a) Viral transmission (b) 
Primary HIV infection (c) Seroconversion stage d) Asymptomatic chronic infection (d) 
The symptomatic stage (e) AIDS defining illness (f) Advanced HIV (g) Death. 
 
HIV enters the human body through blood, serum or vaginal secretions. HIV is spread 
most commonly during sexual intercourse with an infected partner, in case of adults. HIV 
also can be transmitted by contact with infected blood, most often by the sharing of 
needles or syringes contaminated with minute quantities of blood containing the virus37. 
Primary infection normally goes unnoticed when blood tests for HIV infection are 
performed. This may be due to lack of specificity and variable severity of clinical 
syndrome38-40. Mononucleosis like clinical syndrome may be associated with HIV 
primary infection40. 50%-70% of HIV infected patients experience a clinical syndrome of 
varying severity during primary infection. This can be established by retrospective 
analysis of patient clinical history39. A number of studies have confirmed that virologic 
and immunologic mechanisms together are associated with the pathogenic mechanisms 
which consecutively are associated with primary HIV infection41-44. During early stages 
of primary infection, cell-mediated and humoral mediated HIV –specific immune 
responses would be observed following the peak viremia45-47.   In addition to these an 
array of cytotoxic T lymphocytes (CTLs) which are specific for HIV proteins and anti-
HIV antibodies would also be detected. Once the virus enters the body, it infects a large 
number of CD4 cells and replicates rapidly. During this acute or primary phase of 
infection, the blood contains many viral particles that spread throughout the body, 
seeding various organs, mainly the gut lymphoid tissue and the lymph nodes. 
 
 During seroconversion stage the body fights the HIV antigens by producing antibodies to 
restore homeostasis. Flu-like symptoms appear in 70% of HIV infected people after 2-4 
weeks of exposure to the virus. The human immune system fights back the virus with B-
cell produced antibodies and Killer T cells (CD8+ T cells); thereby considerably reducing 
HIV levels.  HIV looks for CD4 molecule with CCR5 and replicates rapidly. Once they 
find CCR5 they bind to these receptor sites on T-Helper lymphocytes and macrophages. 
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Macrophages especially in the genital area are rich in CCR5. HIV can be found in lymph 
after 2 days of infection and in blood after 5 days of infection. After 7 days tests detect 
the presence of HIV antigens. During early stages of primary infection, cell-mediated and 
humoral mediated HIV –specific immune responses would be observed following the 
peak viremia 41, 44, 47 .In addition to these, an assembly of CTLs which are specific for 
HIV proteins and anti-HIV antibodies would also be detected. 
 
 HIV- specific CTLs play a key role in the down regulation of viral replication. The 
vigorous immune response observed during early primary infection fails to eradicate the 
virus as the virus gets transformed from primary infection phase to chronic phase. During 
this chronic phase there would be a down regulation of HIV. However, viral replication 
would not be curtailed. The progression of HIV primary infection to AIDS would take 
eight – ten years48, 49. During this period of latency, HIV continuously and actively 
replicates at the lymphoid organs which serve as anatomic sites of replication50-52. This 
confirms the reality that clinical latency is not equivalent to disease latency. The virus 
may hide within the chromosomes of an infected cell and be shielded from surveillance 
by the immune system. Antiretroviral drugs attack only the replicating viruses and are not 
effective against latent reservoirs of the virus. There would be high turnover of CD4+ T 
cells during this stage where a large number of them are exhausted and restored daily.  
Latent phase is characterised by progressive loss of CD4+ T cells and persistent 
replication50, 53. Through the correlation of CD4+ T cells and development of clinical 
symptoms it can be understood that patients with a CD4+ T cell count > 500 cells/µl 
remain symptom free while patients with <500 cells/µl more frequently associated with 
appearance of constitutional symptoms. When the count falls below 200 cells/µl, there 
would be an increased vulnerability to opportunistic infections or neoplasms54 . Thus, 
evaluation of the progression of HIV disease can be made based on the CD4+ T cell 
counts.  This period of symptomatic stage of HIV infection is complicated by bacterial, 
fungal and viral infection like Pneumocystis jiroveci, Cytomegalovirus, Herpes Simplex 
virus, Mycobacteria, Influenza, Cryptococcus and Candida55-59.   
 
In the category of AIDS defining and/or advanced stage disease HIV infected individuals 
would have a CD4+T cell count of < 200 cells/µl. At this stage there would be 
equilibrium of viral load between peripheral blood and lymph nodes60. Profound 
immunosuppression is the characteristic of advanced stage disease where HIV-specific 
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cytotoxic activity would have been lost at this point61. In this stage, contrasting to the 
decreased number of CD4 T cells would be an increased number of cytokines such as 
INF-γ and IL-1062 . Hence, this reflects that CD8+ T cells and monocytes/macrophages 
account for most of the mononuclear cells after the exhaustion of CD4+ T cells. Severe 
immunosuppression due to destruction of lymphoid tissue is the principal mechanism 
responsible for advanced/late stage HIV disease. Hence with complete depletion of 
immunity and acquiring life threatening opportunistic infections, the patient progressively 
sets off towards death36. Hence, upon observing the various stages of HIV pathogenesis it 
can be said that start of HIV therapy should be initiated during primary infection stage 
when a HIV-specific immune response is likely to be high.   
 
1.2 HIV Testing  
HIV testing is done in two phases. The first phase is diagnosis and monitoring viral load 
is the second phase. In diagnosis, HIV antibodies are detected. Monitoring of HIV 
infection is primarily done by Viral Load (VL) testing. This method is considered highly 
specific63. It looks for viral RNA and has a sensitivity of 50 copies of virus/ml blood. The 
commonly employed blood tests are ELISA (Enzyme Linked Immuno Sorbent Assay) 
and Western Blot which is considered gold standard and more specific than ELISA64, 65. 
These tests are used for the diagnosis of HIV antibodies.  High titers of these antibodies 
would appear during the stage of seroconversion38, 39 . 
 
1.2.1 Following up of the Progression of HIV infection 
 Progression of HIV pathogenesis can be established by periodically monitoring CD4+ T- 
cells, viral load (VL), CD4/CD8 ratio and CD4%36. 
 
 
Traditionally CD4 T- cells and VL are considered the best markers. The lower the 
CD4/CD8 ratio goes the worse the condition of the patient. CD4% gives an insight about 
the patient’s immune system66. Higher the CD4%, the better it is for the patient. Non-
HIV patients have CD4% > 50%, well established HIV patients have 20-35% and HIV 
immunodeficient patients have <15%.  
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1.2.2 HIV affects immune system 
One of the proteins, named gp 120, recognizes a protein on helper T-cells named CD4, 
and associates with it. Gp 120 is a sugar-containing protein called a glycoprotein, which 
has a molecular weight of approximately 120,000.  The CD4 protein is a normal part of a 
helper (both Th1 and Th2) T-cell membrane. The CD4 is a specific receptor for HIV. As 
a consequence of the interaction with CD4 on helper T-cells, HIV exclusively infects the 
cells necessary to activate both B-cell and cytotoxic T-cell immune responses. Without 
helper T-cells, the human body cannot create antibodies appropriately, nor can infected 
cells containing HIV be properly eliminated. As a result, the virus would become capable 
to multiply, kill the helper T-cell in which it survives, infect adjacent helper T-cells, and 
repeat the cycle. These cycles will carry on until there is a substantial loss of helper T-
cells.  
 
The interaction between the virus and the immune system for supremacy is continuous. 
Human body counters to this onslaught through production of more T-cells, some of 
which mature to become helper T-cells. The virus eventually infects these targets and 
eliminates them. More T-cells would be produced, which in due course get infected and 
killed by the virus. This interaction may continue for up to ten years before the body 
eventually succumbs due to an inability to produce T-cells any-longer. This loss of helper 
T-cells ultimately results in the complete inability of the body to protect against even the 
weakest of organisms (all kinds of bacteria and viruses other than HIV) which usually 
would not be very harmful to humans. Thus people with HIV become more susceptible to 
infections and may possibly get certain kinds of cancer that a healthy body would be able 
to fight off. Hence, infections which are rarely seen in people with normal immune 
systems are deadly to those with HIV. This acquired form of immunodeficiency is called, 
AIDS. Even though AIDS is always a result of HIV infection, not all people who become 
infected by HIV develop AIDS.  
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1.2.3 HIV and co-receptors 
Chemokine receptors are the proteins present on the cell surface that bind to small 
peptides called chemokines67, 68. Based on the number and location of conserved 
cysteines the chemokines are classified intro three groups; C, CC and CXC. The role of 
chemokine receptor gene CCR5 has been of strong interest since the discovery of its role 
in the entry of HIV-1 into human CD4 +ve cells69. Chemokine receptors of major 
importance for entry of HIV into human cells are CCR5 and CXCR470-72Conformational 
changes in viral envelope gets provoked by attachment of CD4-gp 120. This allows CD4-
gp 120 complex to interact with either CCR5 or CXCR4; as shown in figure 1-8. On the 
basis of cell tropism HIV can be classified into 2 categories; M-Tropic (macrophage 
tropic) and T-Tropic (T-cell tropic). T tropic strains operate with the CXCR4 co-receptor; 
while M-tropic strains operate with the CCR5 co-receptor 73. Based on the receptor 
action, T-tropic and M-tropic strains are called X4 and R5 viruses respectively67.  
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Figure 1-8 HIV and co-receptor entry67.  The figure 1-8 illustrates a) CD4-gp 120 binding 
b) gp 120-coreceptor interaction c) viral and cell membrane fusion. 
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1.3 Treatment for HIV/AIDS 
Drugs used in the treatment of infection by retroviruses are termed “antiretroviral drugs” 
(ARVs). Several classes of antiretroviral drugs have become available to treat infections 
by retroviruses since 1985. These different classes of ARVs operate at different stages in 
the life cycle of HIV. However, a revolution in the field of HIV medicine occurred in 
1996 when “Highly Active Anti-retroviral Therapy” (HAART) was introduced74. This is 
a drug regimen involving a combination several ARVs, generally ≥ 3, to restrict viral 
replication and possible mutations74, 75.  
 
1.3.1 Highly Active Anti-retroviral Therapy (HAART) 
Extensive research in the area of AIDS has resulted in the development of more than 20 
anti retroviral drugs approved by FDA. Highly active antiretroviral therapy (HAART) has 
been responsible for a dramatic decrease in AIDS mortality since 1996. There has been a 
phenomenal drop in the HIV related mortality and morbidity since the introduction of 
HAART74, 76 . Death rates and AIDS related illness have reduced drastically by 80% 
since HAART is introduced77. The higher the number of the virus inside the human body, 
higher the possibility of resistance to ARVs. Hence a combination therapy of ARVs 
suppresses HIV replication and protects against emergence of resistance. HAART 
substantially reduces viral replication and thus reduces the number of new viral copies 
formed and also the possibility of a superior mutation. HAART usually comprises of a 
combination of two NRTIs and one NNRTI or PI. Even though HAART has been quite 
useful in controlling HIV, extensive and prolonged exposure to three or more ARVs 
poses a major hurdle due to emergence of toxicities and adverse effects76. 
 
The aim of HAART is to control the levels of HIV RNA such that they remain at 
undetectable levels (50copies/ml). Initiation of HAART has totally transformed the 
clinical profile of HIV/AIDS; from a subacute lethal disease to a chronic ambulatory 
disease.  
 
Introduction of HAART resulted in profound suppression of HIV replication and 
significant increase in CD-4 T cell counts78. There has been a remarkable decrease in the 
number of deaths due to AIDS (Figure 1-9), new AIDS cases over the past decade and an 
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increase in the number of people surviving with AIDS in Europe and North America. 
This can be attributed to the improvements in diagnosis and treatment. However, fairly 
few people from underprivileged countries have received this benefit. 
 
 
 
Figure 1-9 HIV and HAART in the United States (1983-2003) 77 
 
1.3.2 Advantages of HAART 
HAART plays a vital role in the reduction in disease progression and in the reduction in 
AIDS diagnosis. Early commencement of HAART may cause reduction in occurrence of 
opportunistic infections which inturn may reduce the extent of hospitalisations79, 80. 
Reduction in AIDS related deaths can be minimised through HAART intervention81. 
1.3.3 Commencing ARVs 
All AIDS cases are individualised. Commencement of ARVs depends upon the patient 
and the clinician. However HAART can be started for all patients with no symptoms but 
have a low CD4 count (<350 cells/ml) or have a high viral load (100,000 cells/ml)82. The 
reason behind this rationale is with time immune competence declines in untreated 
patients and further more sets of T cells would get exhausted. Secondly, there is always a 
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threat of emergence of quasi-species which increase with time on emergence of mutations 
which results in formation of syncytia-inducing (SI) form of virus. The SI form of the 
virus is undoubtedly a more aggressive form of HIV. Hence earlier commencement of 
ART might prevent the emergence of SI form of HIV and may possibly prevent rapid cell 
death.  
Early commencement of ARVs is advantageous as it may cause earlier suppression of 
viral replication and prolongation of disease- free life .This aids to preserve immune 
function and also prevents drug related toxicities. However, for a simple understanding of 
when to commence ARV therapy Wood et al80; described as shown in figure 1-10. 
 
 
Figure 1-10  Commencement of ARVs; Figure 1-10 describes the guidelines regarding 
considerations for the optimal time to initiate HAART80. 
 
1.3.4  Disadvantages of early commencement of ARVs 
Early commencement of ARVs may not always be most favourable as it may expose the 
patients to adverse effects early on and there would be high chances of emergence of 
resistance with suboptimal regimens83, 84. This may lead to limitation of future options of 
ARVs for the patient85. 
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1.3.5 Adherence to HAART 
 
HAART often comprises of a complex regimen86. With HAART adverse events are 
frequent. This may lead to dose interruptions, discontinuation of therapy and considerable 
decline in quality of life. Adverse events pose the main reason for compromise to 
adherence. HAART fails in approximately half of the patient population and non-
adherence plays an important role to some extent87.  Hence, adherence is recognized as an 
important determinant to successful ARV therapy. Virological failure of potent ARVs 
was mostly attributed to poor adherence. Several studies have strongly supported the 
association between adherence and adverse events of ARVs. Surveys of people receiving 
HAART have proved that adverse effects account for 10-15% or more of those patients 
who discontinue therapy and 30% of patients missed doses in their first three days of 
therapy. Adherence was considered a barrier to ARV treatment success88. Near perfect 
adherence is required for successful treatment outcomes in HIV. 
 
Adherence necessitates a healthy and reliable trusting patient-physician relationship, 
wherein the patient should be made the active participant89. The physician should explain 
thoroughly to the patient before the first prescription of HAART. This should include 
knowledge of treatment and possible adverse effects. Involvement of family, friends, and 
support staff improves adherence. A patient’s ability to identify treatment regimen and 
understanding the relationship between adherence and medication resistance also predict 
better adherence90. 
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Table 1-5   Possible strategies to improve adherence to antiretroviral therapy 86 
Medication related: 
Inform, anticipate and treat side effects 
Avoid adverse drug interactions 
Reduce dose frequency and number of pills if possible 
Patient related: 
Negotiate a treatment plan that the patient understands to which he/she commits 
Take time to educate and explain goals of therapy and need for adherence 
Recruit family and friends to treatment plan and need for adherence 
Provide written schedule of medications, daily or weekly pill boxes, alarm clocks 
or other devices 
Develop adherence support groups or add adherence to regular agenda of support 
groups 
Physician related: 
Establish trust 
Serve as educator and source of information, ongoing support and monitoring 
Monitor ongoing adherence and intensify management in periods of low adherence 
Use health care team for difficult patients and patients with special needs, such as 
peer educators for injection drug users or adolescents 
Consider impact of new diagnoses on adherence, particularly depression, and drug 
use 
Health team related: 
Use nurses, pharmacists, peer educators, volunteers, and drug counsellors to 
reinforce adherence 
Provide training to support team related to adherence 
Add adherence interventions to job descriptions of support team members 
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Factors that influence adherence:  
 
The various possible factors which could aid in maintenance of adherence can be 
understood from figure1-11; 
 
 
 
Figure 1-11 Factors which could aid in adherence91 
 
1.4 HIV/AIDS Treatment 
 The following classes of drugs are included under HAART; 1) Nucleotide Reverse 
Transcriptase Inhibitors(NRTIs) (2) Nucletide Reverse Transcriptase Inhibitors (NtRTIs) 
(3) Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) (4) Protease Inhibitors 
(PIs) (5)Novel agents which includes; immune stimulators, vaccines,  integrase 
inhibitors, antisense drugs and entry inhibitors like chemokine co-receptors antagonists, 
attachment inhibitors and entry inhibitors.  Sites of action of the various classes of ARVs 
can be observed from figure1-12. 
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Figure 1-12 Sites of action of current and investigational antiretroviral agents for 
treatment of HIV infection92. 
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1.4.1 Nucleoside Reverse Transcriptase Inhibitors 
The following drugs are included in Nucleoside Reverse transcriptase Inhibitors; 
 
Table 1-6 NRTI 
Brand Name Generic Names Abbreviation 
Combivir Zidovudine + Lamivudine AZT + 3TC 
Emtriva Emtricitabine FTC 
Epivir Lamivudine 3TC 
Epzicom/Kivexa Abacavir + Lamivudine ABC+ 3TC 
Retrovir Zidovudine AZT or ZDV 
Trizivir Abacavir + Zidovudine + Lamivudine ABC + AZT + 3TC 
Truvada Tenofovir + Emtricitabine TDF + FTC 
VIDEX Didanosine ddl 
VIDEX EC Didanosine: delayed-
release capsules ddl 
Viread Tenofovir DF TDF 
Zerit Stavudine d4T 
Zerit XR Stavudine: delayed-release d4T 
Ziagen Abacavir ABC 
 
1.4.2 Non-Nucleoside reverse Transcriptase Inhibitors 
The following drugs are included in Non Nucleoside Reverse Transcriptase inhibitors; 
 
Table 1-7 NNRTI 
Brand Name Generic Names Abbreviation 
Rescriptor Delavirdine DLV 
Sustiva Efavirenz EFV 
Viramune Nevirapine NVP 
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1.4.3 Protease Inhibitors 
The following drugs are included under Protease inhibitors; 
Table 1-8 PIs 
Brand Name Generic Names Abbreviation 
Aptivus Tipranavir TPV 
Crixivan Indinavir IDV 
Invirase Saquinavir (hard gel cap) SQV (HGC) 
Kaletra Lopinavir/Ritonavir LPV/r 
Levixa Fosamprenavir FPV 
Norvir Ritonavir RTV 
Prezista Darunavir  
Reyataz Atazanavir ATV 
Viracept Nelfinavir NFV 
 
1.4.4 Entry/Fusion Inhibitors 
The following drugs are included under entry/fusion inhibitors; 
Enfuvirtide(T20) 
1.4.5 Fixed dose combinations of ARVs 
Table 1-9 combinations of anti-retrovirals drugs 
Brand Name Generic Names Abbreviation 
Atripla Efavirenz + Emtricitabine + 
Tenofovir) 
EFV + FTC + TDF 
Combivir Zidovudine + Lamivudine AZT + 3TC 
Trizivir Abacavir + Zidovudine + 
Lamivudine 
ABC + AZT + 3TC 
Truvada Tenofovir + Emtricitabine TDF + FTC 
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1.4.6 Dosage Forms of the available anti-retrovirals 
Table 1-10 Dosage forms 
Generic Name Brand and Other names Capsules Tablets 
Liquid 
Form IV 
Abacavir Ziagen, ABC       
Abacavir,Lamivude Epzicom      
Abacavir,Lamivudine, 
Zidovudine Trizivir      
Didanosine 
VIDEX 
ddl, VIDEX 
EC 
 
Chewable 
enteric 
coated 
tablet 
Buffered 
powder 
can be 
dissolved 
 
Emtricitabine Emtriva, FTC, COVIRACIL       
Emtricitabine, 
Tenofovir DF Truvada  
Film 
coated 
tablet 
  
Lamivudine Epivir, 3TC  
Film 
coated 
tablet 
Flavoured  
Lamivudine, 
Zidovudine Combivir      
Stavudine Zerit, d4T       
Tenofovir DF Viread, TDF      
Zidovudine Hivid, ddC         
Delavirdine Rescriptor, DLV    
Can be 
dissolved  
Efavirenz Sustiva, EFV       
Nevirapine Viramune,NVP       
Atazanavir Reyataz, ATV      
Fosamprenavir Lexiva, FPV      
Indinavir Crixivan, IDV      
Lopinavir/Ritonavir Kaletra, LPV/r       
Nelfinavir Viracept,NFV    Oral Powder  
Ritonavir Norvir,RTV       
Tipranavir Aptivus,TPV      
enfuvirtide Fuzeon,T-20    Injection 
only 
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1.4.7 Anti-retroviral Agents approved by FDA 
Mechanism of action of NNRTIs 
NNRTIs reversibly inhibit HIV-1 reverse transcriptase reducing viral DNA synthesis. 
 
Table 1-11 FDA approved NNRTIs 
NNRTIs Dosing Frequency Daily Pill burden Common side-
effects 
Nevirapine  
Twice daily 
2 Rash, elevated liver 
enzymes 
Efavirenz Once daily 1 or 3 
 
Rash, Nervous 
system symptoms 
Delavirdine Three times daily 6 Rash 
 
 
Mechanism of action of NRTIs 
 
NRTIs are converted by cellular enzymes to active phosphorylated metabolites that 
inhibit viral reverse transcriptase and viral DNA synthesis, preventing HIV replication. 
The specific site of action differs for each drug; these differences are exploited in 
combination regimens. They act as false substrates for reverse transcriptase and thereby 
causing chain termination. The resulting viral DNA is incomplete and prevents HIV 
replication86, 93. NRTIs and NtRTIs are derivatives of naturally occurring nucleosides that 
make up DNA. Similar to all naturally occurring nucleosides NRTIs need to be tri-
phosphorylated. The tri-phosphorylated form is an active form which competes with the 
natural deoxy-nucleotide tri-phosphates for incorporation into growing DNA chains and 
following incorporation into DNA, by DNA chain termination. As a result a full length 
copy of the DNA is not produced. 
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Table 1-12 FDA approved NRTIs 
NRTIs Dosing Frequency Daily Pill burden Common side-
effects 
Zidovudine Twice daily 2 GI 
Didanosine Twice daily 
Once daily 
2-4 
1 
Peripheral 
Neuropathy 
Stavudine Twice daily 2 Peripheral 
Neuropathy 
Lamivudine Twice daily 
Once daily 
2 
1 
GI 
Lamivudine/ 
Zidovudine 
Twice daily 
 
2 GI 
Abacavir Twice daily 2 GI, Allergic reaction 
Abacavir/ 
Lamivudine 
Once daily 1 GI, Allergic reaction 
Abacavir/ 
Lamivudine/ 
Zidovudine 
Twice daily 2 GI 
Emtricitabine Once daily 1 Headache, GI 
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Mechanism of action of NtRTIs 
 
Tenofovir is metabolised to active Tenofovir diphosphate which inhibits viral 
polymerases and terminates the DNA chain after incorporation into viral DNA93. 
Table 1-13 FDA approved NtRTIs 
NtRTIs Dosing 
Frequency 
Daily Pill burden Common side-
effects 
Tenofovir Once daily 1 GI 
Tenofovir/Emtricitabine Once daily 1 Headache, GI 
 
 
Mechanism of action of Protease Inhibitors  
 
Inhibit HIV-1 and HIV-2 proteases preventing maturation and replication94, 95 . 
 
Table 1-14 FDA approved PIs 
PIs Dosing Frequency Daily Pill burden Common side-
effects 
Saquinavir mesylate Twice daily (with 
Ritonovir) 
 
12 GI 
Indinavir Three times daily 
Twice daily(with 
ritonovir) 
6 
6-8 
Nephrolithiasis, GI 
Ritonovir Twice daily 12 GI, dyslipidemia 
Nelfinavir Three times daily 
Twice daily 
9 
4-10 
GI 
Lopinavir/Ritonavir Twice daily 6 GI 
Atazanavir Once daily 
Once daily(with 
ritonavor) 
2 
3 
Benign 
hyperbilirubinemia 
Fosamprenavir Twice daily 
Twice daily(with 
ritonavir) 
Once daily (with 
ritonavir) 
4 
4 
 
4 
Rash 
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Mechanism of action of Fusion Inhibitors 
 
They bind to viral glycoprotein subunit gp41 and by inhibiting its function, block viral 
fusion with the CD4 receptor of the host cell and thus viral entry to the cell96.  
 
 
Table 1-15 FDA approved Entry Inhibitors 
Entry Inhibitors Dosing Frequency Daily Pill burden Common side-
effects 
Enfuvirtide(T20) Twice daily 2 SC injections Injection site 
reactions 
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1.5  Nevirapine Pharmacology 
 
 
Figure 1-13 Nevirapine chemical structure 
                                        
The chemical name of NVP is 11-cyclopropyl-5,11- dihydro-4 methyl-6H-dipyrido[3,2-
b:2’,3’-e][1,4]diazepin-6-one97. 
NVP is a white to off- white crystalline powder with molecular weight of 266.3 and 
molecular formula C15H14N4O. NVP is low- molecular weight compound. It is weakly 
basic with a pKa of 2.8 and highly lipophilic with partition coefficient of 8398. NVP is 
extremely soluble at pH < 3 but at neutral pH its aqueous solubility decreases to 0.1 
mg/ml98. The absolute bioavailability is approximately 90%99 . It is 50%-60% protein 
bound. NVP absorption is not affected by concomitant administration of food, didanosine 
or antacids. NVP concentration in human CSF is 45% of that found in plasma, which is 
almost equal to the plasma free fraction which is not bound to plasma protein. NVP was 
shown to cross the blood-brain barrier (BBB) more effectively than other anti-retroviral 
drugs like didanosine, stavudine, zidovudine, delavirdine, indinavir or saquinavir100.It is 
proven that use of NVP can show beneficial effects in the elimination of HIV-1 induced 
dementia because of its ability to cross BBB and accumulate in CSF101. The volume of 
distribution is 1.21 ± 0.09 L/Kg. Metabolism of NVP is mediated by 3A4 family of 
isoenzymes of the CYP-450 system resulting into the formation of glucuronides 
ultimately. This is confirmed by in vitro studies with human liver microsomes. 
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Approximately 80% of the given dose of NVP is recovered from urine primarily as 
glucuronide conjugates of hydroxylated metabolites while 10% was found in faeces. 
Table 1-16 gives a brief idea about the pharmacokinetics of NVP. 
 
 
Table 1-16 NVP Pharmacology102 
Parameter Dose 
AUC µg h/ml Adult: 55.95(51.49-69.74) 
 
Infant: 62.6 ± 15.7 
 
C max (µg/ml) Adult: 5.86(5.52-7.22) 
 
Infant: 1.24 ± 0.34 
 
t max (h) Adult: 2-4 
 
Infant: 14 ± 8.9 
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Pharmacokinetics of other common ARVs  shown in Table 1-17. 
 
Table 1-17 Pharmacology of other important antiretroviral drugs103 
Drug Volume of 
distribution 
L/Kg 
Renal Clearance Half life 
hours(h) 
Protein 
Binding 
(%) 
Bioavailability 
(%) 
Zidovudine 1.6 400ml/min/70kg 1.1 25 60-70 
Lamivudine 1.3 260ml/min 2-4 36 82 
Didanosine 1 400ml/min 1.4 <5 25-43 
Satavudine 0.5 240ml/min 1.6 Negligible 80 
Delavirdine Not Reported Not available 2.8-7.3 99 Well absorbed 
Saquinair 10 Not Reported 13 98 4 
Ritonavir 0.5 <0.1 L/hr 3-5 99 60 
Indinavir 2.25 Not Reported 1.8 60 Well absorbed 
Nelfinavir 2-7 Not Reported 3.5-5 >99 30 without food 
& 43 with food 
1.5.1  Adverse effects associated with Nevirapine 
Nevirapine was approved by the FDA in 1996 and since then it has exhibited impressive 
results and gained an authoritative place in the treatment of HIV infection. NVP is 
usually a well tolerated ARV drug86. However, rash is the most common adverse effect 
that necessitates discontinuation if severe. Rash usually tends to occur during the first few 
weeks of therapy. The occurrence of rash was observed in 17% of the patient population 
as stated by Murphy et al104.  Patients who experience rash during the first two weeks of 
therapy should be educated not to increase the dose of NVP. Rash due to NVP is 
generally mild- moderate in severity which typically appears on the face, trunk and 
extremities105 . They are maculopapular, erythematous cutaneous eruptions with or 
without pruritis. However, rare and life-threatening skin reactions may also occur in 
patients using NVP 106. The role of HLA molecules in the hypersensitivity reactions to 
NVP therapy can be attributed to HLA class I alleles HLA-Cw-08, HLA B-14 and HLA-
DR1 where NVP or its metabolite when coupled with HLA antigens may be expressed on 
the cell surface and may bring about   NVP hypersensitivity reactions or hepatotoxicities. 
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Management of NVP related rashes must be based on their severity. Mild-moderate 
rashes (Grade 1-2) are usually limiting and the rashes usually resolve without 
discontinuing NVP therapy. Use of oral anti-histamines or topical steroid creams may be 
sufficient to control grades 1-2 rashes. Rash along with gastrointestinal manifestations 
(characterised by diarrhoea), severe pruritis, vomiting, oral lesions and/or ulceration, 
muscle or joint pains mandates the discontinuation of NVP. NVP should not be 
rechallenged in these patients.  
 
Hepatotoxocity is recognized to be a major safety concern with the use of NNRTIs107. 
Development of severe hepatotoxocity has been linked with the use of NVP 108. 
Progression of liver disease would be accelerated in HIV-1 patients who are co-infected 
with HBV or HCV and hence is a concern as their condition would deteriorate further if 
they were placed on NNRTIs109. 
Hepatotoxicity associated with NVP was found with chronic dosing and not with a single 
dose110.  However, there is a high risk (17%) of early hepatotoxicity with the use of 
NVP111, 112 .  
 
 
 
The common adverse effects associated with NNRTIs are listed in Table 1-18. 
 
Table 1-18 NNRTI adverse effects86 
NNRTI adverse effect % of patients affected 
Rash, total 17-24 
Rash, severe 4-8 
Stevens-Johnson syndrome 0.5 
Fever 5-10 
Elevated AST and ALT levels, and/or GGT 3-8 
Nausea 7-11 
Headache 7-10 
 
 38 
1.5.2  Role of NVP in Mother-To-Child- Transfer of HIV 
Mother-To-Child-Transfer (MTCT) is a very important source of HIV infection in 
children and breast-feeding may be a major risk in such cases and chances of acquiring 
HIV is doubled to the child113, 114. However, the HIVNET 012 (The HIV Network for 
Prevention Trials) established the safety and efficacy of NVP in the prevention of MTCT. 
In the HIVNET pregnant women received a single dose of oral NVP during labour and 
the new born received one dose of NVP (2mg/kg) within 72 hours of birth. The single 
dose of NVP was administered alongside the usual dose of Zidovudine to the mother. The 
results of HIVNET 012 have been substantiated by other studies115-118.  
 
1.5.3  Nevirapine Resistance 
Studies performed prior to HIVNET 012 demonstrated the rapid emergence of NVP 
resistance upon monotherapy119-121. Although NVP has proved efficacious to prevent 
MTCT, further research revealed that there exists a high chance of getting NVP 
resistance due to the emergence of viral mutations even with a single dose of NVP. The 
Y181C mutation was most commonly observed in the infants from the HIVNET studies. 
However, K103N mutation was also observed in the study. The results were confirmed 
by PACTG 316 trial where 11% of the women were found to have NVP resistance122. A 
detailed explanation about NVP resistance was provided by Giovanni Maga et al123; 
stating that NVP resistance could occur due to combination of emergence of steric and 
thermodynamic barriers for drug binding and loss of stabilizing interactions123. 
1.5.4 Adverse reaction with NRTIs 
 
NRTIs have been the foundation for HIV therapy since the availability of Zidovudine in 
1986. Ever since, a range of NRTIs have been invented. All of them have the same 
mechanism of action but many adverse effects of each agent are quite unique. In order to 
elicit an effect on HIV, NRTIs first must be phosphorylated intracellularly by the host 
specific cell enzymes. But the major untoward effect with NRTIs is that they not only 
inhibit HIV reverse transcriptase but also cellular DNA polymerases; mitochondrial 
polymerase γ leading to mitochondrial toxicity. Most common adverse effects with 
NRTIs are lactic acidosis with severe hepatomegaly and steatosis. Relationship between 
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genetic markers and ARV drug hypersensitivity reactions with Abacavir have been 
identified in previous studies. The major treatment-limiting side effect associated with the 
use of Abacavir is an early onset multi-system drug hypersensitivity reaction which 
includes combination of rash, fever and gastrointestinal symptoms, occurring within 6 
weeks of initiating treatment. Susceptibility to Abacavir hypersensitivity is strongly 
predicted by the presence of a specific HLA allele - HLA-B57 which characterizes the 
prevailing risk factor for the drug’s hypersensitivity reactions. However the common 
adverse effects with NRTIs are listed in Table 1-19 
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Table 1-19 NRTI adverse effects86 
NRTI, adverse effect % of patients affected 
Zidovudine  
Headache 12 18 
Fatigue 2 7 
Neutropenia 2 31 
Nausea 4 26 
Anaemia 1 7 
Insomnia 4 5 
Vomiting 3 8 
Myalgia 5 8 
Myopathy 6 18 
Didanosine  
Pancreatitis 5 9 
Diarrhoea 15 28 
Peripheral neuropathy 2 20 
Elevated AST and ALT levels 6 10 
Stavudine  
Peripheral neuropathy, total 13 24 
Gastrointestinal 4 6 
Headache 3 5 
Elevated AST and ALT levels 5 10 
Lamivudine  
Nausea 4 
Headache 8 
Fatigue 4 
Insomnia 4 
Abacavir  
Nausea/vomiting 5 15 
Fever 5 7 
Dizziness 5 10 
Insomnia 2 7 
Rash 3 5 
Diarrhoea 1 12 
Hypersensitivity reaction 3 5 
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1.5.5 Adverse effects with PIs 
To prevent emergence of resistance, PIs require accurate dosing, and adherence must be 
maintained. Since the risk of emergence of drug resistance is superior to the potential 
danger of adverse events, it is always advisable to maintain adherence. Hence it is not 
advised to reduce the dose of a PI drug in an attempt to reduce the adverse effects. 
Alongside other adverse effects of PIs, reports about syndrome of metabolic disorders 
have been identified in patients receiving PIs compared to those patients who are PI naive 
and the ones whose treatment is PI-sparing. The common adverse effects observed in PIs 
are listed in Table 1-20.  
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Table 1-20 PI adverse effects86 
 
 
PI, adverse effect % of patients affected 
Saquinavir  
Diarrhoea 20 
Nausea 11 
Abdominal pain 9 
Dyspepsia 8 
Flatulence 8 
Headache 5 
Fatigue 5 
Elevated AST and ALT levels 2-6 
Indinavir  
Diarrhoea 5 
Vomiting 4 
Hyperbilirubinemia 10 
Abdominal pain 9 
Nausea 12 
Headache 6 
Ritonavir  
Nausea 23-26 
Diarrhoea 13-21 
Taste perversion 5-15 
Elevated AST and ALT levels 5-6 
Asthenia 9-14 
Headache 5-6 
Vomiting 13-15 
Anorexia 6-8 
Perioral dysesthesia 3-6 
Hypertriglyceridemia 2-8 
Hypercholesterolemia 2 
Nelfinavir  
Diarrhoea 14-32 
Nausea1 3-7 
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2       Methodology 
2.1  Ethical approval 
The study involved the collection and analysis of patient’s recorded data, therefore 
ethical approval was obtained from Curtin University of Technology Human Research 
Ethics committee (Appendix). As this study involved the analysis of patient records, 
ethical issues arise in relation to confidentiality and release of data. A unique non-patient 
identifiable code (Unit Medical Record Number; UMRN) was allocated to each patient. 
The key to the code was held at all times by the Head of Department of Clinical 
Immunology, Royal Perth Hospital. Any coded data to leave the hospital was kept secure 
in accord with National Health and Medical Research Council guidelines and only group 
data will be released from the research. The data will be stored in the School of 
Pharmacy, Curtin University of Technology for a period of seven years in a locked 
cabinet.  
 
2.2 Setting and Patient Population 
The research was conducted at the Department of Clinical Immunology, Royal Perth 
Hospital (RPH), Western Australia. An extensive database held in the Department of 
Clinical Immunology was accessed for patient clinical records.  The research was based 
on the review of the entire HIV database available at the Department of Clinical 
Immunology. HLA typing was done based on the data available from serological HLA 
typing and sequential typing. Various alleles of IL-1 alpha were determined by 
polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). 
The researcher utilized only data from the hospital database and the experimental 
procedures required for the study included methods like PCR and RFLP were performed 
by the staff of the Department of Clinical Immunology, Royal Perth Hospital. 
Experimental procedure for IL-A genotyping was undertaken according to the method 
published by Price et.al12.  
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2.2.1  Inclusion Criteria 
The research included all the patients who received Nevirapine as part of the first 
regimen of anti-retroviral drugs. Patients who received any other anti retroviral drug prior 
to receiving NVP were not included in the study.  All patients whose data was derived 
from the database were over 18 years of age and received NVP as their first drug of 
treatment. Adult HIV infected patients were considered for the research. RPH is the 
referral centre for patients with AIDS/HIV for the state of Western Australia.  
 
2.2.2 Data Collection 
The patient population was divided into three groups based on their length of stay on 
Nevirapine; short-term, medium and long-term responders.  Patients who stayed on 
Nevirapine continuously for more than five years were considered long-term responders 
(60+ months or >60 months)). Patients who withdrew before six months of therapy due to 
the drug’s side effects or for any other reason were considered short-term responders (0-6 
months or <6 months). Patients whose length of stay on the drug is intermediate between 
these two groups are considered as medium responders (6-60 months). There were almost 
500 cases of HIV in the hospital during the period of study. These cases were entered in 
Microsoft excel sheets and were randomized for selection. However, only patients to 
whom NVP was given as the first drug for treatment were taken into this study; hence the 
patient population in the study was only 79. 
We considered several factors that might determine whether a patient on NVP would be a 
long term responder or a short term user of the therapy,  based on the results of 
previously published studies124.   
 
Factors considered for the study were: 
1. Age 
2. Sex 
3. Baseline CD4 T cell count 
4. Baseline Viral load 
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5. History of IV drug use 
6. Genetic factors previously associated with the development of nevirapine toxicity   
or long-term control of HIV replication. The genetic factors include;  
         a) IL-1A genotype 
      b) HLA genotype 
The genetic markers which were examined as predictors of effective NVP long term use 
are; 
 
1) IL-1A alleles, which have been associated with a good virological response to any 
antiretroviral therapy12. 
2) Class I and II HLA molecules, which have been associated with NVP 
hypersensitivity reactions125. 
 
2.2.3 Research Method 
The research was based on the survey of the entire HIV database available at the 
Department of Clinical Immunology; Royal Perth Hospital. HLA typing was done based 
on the data available from serological HLA typing and sequential typing. Various alleles 
of IL-1A were determined by polymerase chain reaction (PCR) and restriction fragment 
length polymorphism (RFLP)12.IL alleles were assessed as restriction fragment length 
polymorphism. Briefly, 150ng genomic DNA was placed in a 50 µl reaction mix 
containing 800µM dNTP, 2mM magnesium chloride, 800µM primers. DNA flanking IL 
was amplified with 1 U Taq platinum polymerase [960C 15 minutes (940C 1 min, 500C 1 
min, 720C 2 min) x 45 cycles, 720C 5 min]. Amplicons were digested overnight with 
Nco1 (370C), separated by electrophoresis on 15% polyacrylamide or 3% agarose gels 
and visualised using ethidium bromide. Plasma HIV RNA was assayed by Amplicor 1.0 
(standard protocol, 400-750 000 copies/ml) (Roche Diagnostic Systems Inc., Branchburg, 
NJ, USA). Only data is used for this study. Techniques like PCR and RFLP were 
performed by the staff of the Department of Clinical Immunology at Royal Perth 
Hospital. 
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2.3 Hypothesis 
Since the research was started with all the patients who had taken NVP as their first drug 
of therapy, the above set of factors were considered to investigate whether or not one of 
the factors would predict the stay of patients on NVP for long time. The factors 
considered for the search to predict the length of stay were; a) Gender b) Mode of 
infection c)Baseline CD4 d)Baseline RNA e)IL-1A genotype f)HLA type, particularly 
HLA- DR1 and HLA-B14, because these have been associated with toxicity in previous 
studies. We hypothesised that any of the above factors would predict the explanation for 
continuing NVP therapy or for discontinuing NVP therapy. If this hypothesis is proved 
correct, we can prevent the NVP induced toxicities to patients by recommending NVP 
only to those patients who are in concordance with the study results.  
 
 The data was taken from the RPH patient information sheet. The following information 
was employed for the present study. 
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Table 2-1 Group I Patient information sheet  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a time of study  
b
 Date of commencement of ART 
c
 CD4 count 
d
 RNA level in  
e  No =  NVP discontinued 
  Yes = NVP continued 
UMRN Sex Age a Code ART 
dateb 
No.of 
months 
Baseline 
CD4c 
Baseline 
RNAd 
IL-1A 
genotype 
Continuinge HLA 
B35+HLAC4 
HLA 
DR1 
HLA  
B14 
Patient 1 M 53 1 28/01/1998 1 650 17608 1,1 No No No No 
Patient 2 M 45 5 24/06/2004 6 396 81283 1,1 No No No No 
Patient 3 M 38 12 15/03/1999 0 396 17099 1,1 No No No No 
Patient 4 F 45 2 10/12/1997 1 286 19415 1,1 No No No No 
Patient 5 M 40 1 14/10/1997 2 240 15543 1,1 No No No No 
Patient 6 M 49 3 19/08/1998 6 260 66089 1,1 No Yes No No 
Patient 7 F 37 2 15/11/2000 1 288 39300 1,1 No No No No 
Patient 8 F 58 2 9/07/1997 1 680 85114 1,1 No No Yes 1Yes 
Patient 9 M 41 1 23/08/2005 1 576 660693 1,1 No No No No 
Patient 10 M 32 1 12/05/1998 1 360 33864 1,2 No Yes Yes No 
Patient 11 F 43 2 27/06/2001 2 405 115000 1,2 No No No No 
Patient 12 M 37 12 5/11/1998 4 300 155479 1,2 No No No No 
Patient 13 M 55 1 8/03/2000 3 180 75000 1,2 No No No No 
Patient 14 M 62 1 15/08/2000 1 280 161000 1,2 No No No No 
Patient 15 M 54 1 1/12/2004 1 240 100000 1,2 No No No No 
Patient 16 F 34 11 11/11/1998 0 616 219111 1,2 No No No No 
Patient 17 M 65 12 15/04/2003 0 1081 ND 2,2 No No No No 
Patient 18 M 52 1 4/03/1998 1 400 39101 2,2 No No No No 
Patient 19 F 31 5 19/01/2002 1 756 11200 NA No No Yes No 
Patient 20 M 34 1 14/11/2000 0 350 719400 1,1 No No No No 
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Table 2-2  Group II Patient information sheet 
UMRN Sex Age a Code ART 
dateb 
No.of 
months 
Baseline 
CD4c 
Baseline 
RNAd 
IL-1A 
genotype 
Continuinge HLA 
B35+HLAC4 
HLA 
DR1 
HLA  
B14 
Patient 21 M 43 1 25/08/1998 11 672 22754 1,1 No No No No 
Patient 22 M 45 1 23/06/1997 21 780 154882 1,1 No No No No 
Patient 23 M 52 1 14/11/1994 22 456 ND 1,1 No No Yes No 
Patient 24 M 32 3 30/07/2001 9 696 52000 1,1 No No No No 
Patient 25 M 32 11 1/04/1998 46 644 115343 1,1 No No No No 
Patient 26 M 43 1 22/12/1997 27 342 5536 1,1 No Yes No No 
Patient 27 M 56 1 15/10/2001 55 255 89300 1,1 Yes No No No 
Patient 28 M 53 3 7/02/1999 12 51 178178 1,1 No Yes No No 
Patient 29 M 40 1 15/02/1997 11 52 389045 1,1 No No No No 
Patient 30 M 52 1 14/12/1994 24 289 ND 1,1 No No No No 
Patient 31 M 44 1 8/04/1998 23 437 84812 1,1 No Yes No No 
Patient 32 M 33 1 21/07/1997 23 100 515355 1,1 No Yes No No 
Patient 33 M 43 1 15/10/1994 25 323 ND 1,1 No No No No 
Patient 34 M 44 1 9/03/1995 43 320 ND 1,1 No No No No 
Patient 35 M 42 1 20/07/2001 12 237 130000 1,2 No No No No 
Patient 36 F 65 2 15/09/2002 44 250 2130 1,2 Yes No No No 
Patient 37 M 44 11 16/01/2001 19 224 41800 1,2 No No Yes No 
Patient 38 M 44 1 7/11/1997 22 640 82823 1,2 No Yes No No 
Patient 39 M 55 2 15/11/2004 18 396 81283 1,2 Yes Yes No No 
Patient 40 M 31 1 11/12/2003 30 531 106000 1,2 Yes Yes No No 
Patient 41 F 39 2 21/12/2001 23 364 30700 1,2 No No No No 
Patient 42 M 71 1 7/12/1994 40 576 ND 1,2 No No Yes No 
Patient 43 M 64 1 15/08/2002 45 44 750000 1,2 Yes No No No 
Patient 44 M 54 1 11/01/1999 32 620 579225 1,2 No No No No 
Patient 45 M 34 1 24/07/2001 58 290 188000 1,2 Yes Yes No No 
Patient 46 F 28 11 5/09/1997 10 322 118779 2,2 No No No No 
Patient 47 F 77 2 15/10/2002 43 148 4900 NA Yes No No No 
Patient 48 M 43 1 30/07/1997 10 462 30200 NA No No No No 
Patient 49 M 56 1 5/05/2005 12 476 14125 1,1 Yes ND No No 
Patient 50 M 47 1 31/05/2005 11 475 100000 1,1 Yes No No No 
Patient 51 M 32 5 9/11/2004 18 84 100000 1,1 Yes No No No 
Patient 52 M 34 3 13/06/2005 11 486 93325 1,1 Yes No No No 
Patient 53 M 37 1 31/08/2005 9 122 100000 1,1 Yes Yes No No 
Patient 54 M 56 1 11/08/2005 9 60 263027 1,2 Yes Yes No No 
Patient 55 M 44 1 17/02/2005 15 266 50119 1,2 Yes No No No 
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Table 2-3 Group III Patient information sheet 
UMRN Sex Age a Code ART 
dateb 
No.of 
months 
Baseline 
CD4c 
Baseline 
RNAd 
IL-1A 
genotype 
Continuinge HLA 
B35+HLAC4 
HLA 
DR1 
HLA  
B14 
Patient 56 M 50 1 15/09/1997 66 195 104702 1,1 No No No Yes 
Patient 57 M 40 11 8/07/1999 60 408 12500 1,1 No No Yes No 
Patient 58 M 33 1 10/11/1997 60 440 82088 1,1 No No No Yes 
Patient 59 M 44 1 15/09/2000 68 549 218000 1,1 Yes No No No 
Patient 60 M 39 10 17/02/1997 111 338 31623 1,1 Yes No Yes No 
Patient 61 M 48 1 17/02/1999 87 391 410663 1,1 Yes No No No 
Patient 62 M 37 3 28/01/1998 83 60 28000 1,1 No No No No 
Patient 63 M 34 1 11/02/1998 99 675 5407 1,1 Yes No No Yes 
Patient 64 M 44 1 15/08/1997 105 234 117350 1,1 Yes No No No 
Patient 65 M 29 3 16/10/1998 91 456 64802 1,1 Yes No No No 
Patient 66 M 43 1 14/10/1998 91 357 4976 1,1 Yes No No No 
Patient 67 F 29 12 2/12/1997 85 285 462674 1,1 No No No No 
Patient 68 M 42 1 15/06/1999 83 420 9515 1,1 Yes No No No 
Patient 69 M 43 1 15/06/1997 85 324 208930 1,1 No No Yes No 
Patient 70 F 39 2 6/05/1998 77 348 17054 1,2 No No No No 
Patient 71 F 43 12 30/09/1998 76 528 21854 1,2 No No No No 
Patient 72 M 47 1 28/01/1998 71 ND ND 1,2 No No No No 
Patient 73 M 47 1 26/08/1998 93 72 110200 1,2 Yes No No No 
Patient 74 M 37 1 10/12/1998 89 612 123479 1,2 Yes No No Yes 
Patient 75 M 61 1 14/05/1999 84 300 34443 1,2 Yes No No No 
Patient 76 M 46 3 11/12/1997 101 594 157692 2,2 Yes No No No 
Patient 77 M 39 1 6/06/1997 107 276 47863 2,2 Yes No No No 
Patient 78 F 29 2 14/10/1998 84 255 7669 NA No No No No 
Patient 79 F 44 2 9/06/1997 101 341 30903 NA Yes No No No 
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 Patient information sheet details 
 
UMRNs of the patients who participated in the study are not provided here due to ethical 
constraints. However, each patient is represented by a patient number. 
 
Data regarding HLA-A, HLA-B, HLA-C, HLA-DRB1 and IL-1A were derived from the HIV 
database for all the patients included in the study. Control caucasian HLA A and B frequencies 
were obtained from the database of bone marrow donors held at RPH (n = 879).  Control HLA 
C and DR frequencies were obtained from the Busselton population study details of which were 
held at RPH (n = 200). 
 
The patient information sheet also allowed the collection of data regarding mode of acquisition 
of virus and is represented by a code as described below. 
 
          
Code = Mode of transfer of HIV  
1 = Male to male sexual contact 
2 = Male to female sexual contact 
3 = Female to male sexual contact 
4 =  Female to female sexual contact 
5 = Sharing of contaminated needles and/or syringes 
6 = Transplacentally or congenitally 
7 = Through breast milk 
8 = Recipient of blood or blood products or tissue transplant or semen 
9 = Needle stick injury or similar acute exposure to material capable of HIV 
transmission                              
10 = Male to male sexual contact and sharing of contaminated needles 
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11 = Male to female sexual contact and sharing of contaminated needles 
12 = Unknown   
             
2.4 Statistical analysis 
Statistical analysis of the data was performed using SPSS version 14 for windows. Chi-square 
(χ2) analysis was used to observe the any significant relationship between categorical variables 
gender and continuity with NVP. A Two –sample T-test was used to determine any significant 
difference between continuous variable; age and categorical variable; continuity of NVP in the 
two groups (Yes and No groups). For continuity of NVP use and for baseline RNA levels, Non-
parametric Mann-Whitney test was performed. Similar to baseline RNA, baseline CD4 in the 
three groups was compared using Non-parametric Mann-Whitney test. P value less than 0.05 
was considered significant. Association between IL-1A and continuity with NVP was analysed 
using Chi-squared test.  
 
2.4.1 Survival Analysis 
 
To determine whether or not all the patients involved in the study truly continued on NVP a 
survival analysis was performed. Data collected contains several patients from groups I, II and 
III do not reveal the continuity on NVP due to lack of relevant data.  Hence to verify whether or 
not the patients received NVP and to eliminate confusion a survival analysis was performed to 
explain the actual time the patients received the drug and taking HLA-B35+HLA-C4 also as 
criteria. A Kaplan Meier survival analysis was performed since it estimates the survival 
function from life-time data.  In this analysis a Yes/No preference was made use of, 
demonstrating that those patients with HLA-B35+HLA-C4 and those without the same 
combination. A Yes-censored and No-censored criterion was used to determine the continuity 
of patient’s use of NVP, declaring that those who continue NVP were Yes-censored and those 
patients who did not continue were No-censored.  
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Survival time refers to the collection of procedures performed statistically to analyse data in 
which the outcome variable of interest is time until an event occurs. Here in our analysis we 
considered continuity with NVP as the outcome variable. While performing survival analysis 
for time on NVP we refer NVP continuity as survival time. Censoring was performed to 
eliminate the survival analysis data since we don’t know the survival time exactly and some 
patients may still continue with NVP or in remission. Survivor functions represent the 
probability of survival of a person or group longer than some specified time. The median 
survival times for group I (without HLA-B35+HLA-CW4) and group II (with HLA-B35+HLA-
CW4) were 91 months and 30 months respectively. From this median survival times we can 
interpret that that group I tend to continue on NVP therapy compared to group II. The Log 
Rank Test can be employed to compare the difference between two survival curves. A p- value 
< 0.05 based on the Log Rank test indicates a significant difference between the two curves.  
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3 Results 
3.1 Patient group comparison 
     A total of 79 patients were included in the study.  The frequency distribution of the length of 
time that patients stayed on NVP therapy is shown in figure 3.1.  
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Figure 3-1 Frequency distribution of patients on Nevirapine according to duration of therapy 
 
3.1.1 Definition of patient groups 
From the above depiction of the data it was clear that a group of patients were discontinued 
from NVP therapy relatively early after commencement of treatment. Based on the clinical 
experience of one of the supervisors of this project (Professor Martyn French) the cut off point 
for this early withdrawal was arbitrarily taken as 6 months (Group I). The relevant data for this 
group are shown in Table 2-1. The remaining patients were then further divided into groups 
according to duration of therapy.  Group II consisted of patients whose therapy had continued 
on the drug for between 6 months and 5 years (data shown in Table 2-2).  Group III consisted 
of those whose treatment had persisted for longer than 5 years.  It should be noted that some 
patients in each group were still taking NVP at the time of the study.  These data are depicted in 
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Table 2-3.  When conducting the survival analysis (section 3.1.9) whether patients were still on 
the drug was taken into consideration. Upon categorizing the population into these three 
groups, analysis of their characteristics was performed. In this analysis the factors considered 
were; sex, age, baseline CD4, baseline RNA, HLA and IL-1A genotype.  
 
 
 
3.1.2 Effect of age on duration of NVP therapy  
The effect of age of commencement on therapy on the ability to remain on long-term NVP was 
analysed in two ways.  In the first those currently on NVP  were compared with those who had 
ceased NVP.   There was no significant difference in age between the two groups, (p = 0.317). 
Two –sample t-test was used. 
 
Secondly, patients in three groups developed according to duration of NVP therapy were 
compared according to their age at the commencement of NVP therapy.  When the patient 
group who had remained on NVP for longer than 5 years were compared with the two groups 
who had discontinued therapy, there appeared to be no significant difference (Table 3-1). 
Hence, this indicates that age does not have an effect on the length of stay on NVP.  
 
Table 3-1 Mean age of patient in each group 
Group Number Mean P value 
I 20 45.25 NS 
II 35 45.97 NS 
III 24 41.12 NS 
 
NS= Not Significant 
 
3.1.3 Effect of gender 
There was no significant relationship between gender and whether or not the subject was 
continuing NVP use (p = 0.165). Chi-squared test was used. On comparing effect of gender to 
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duration of time on NVP, no significant association was observed (Table 3-2). Thus, results 
show that there existed no relation between gender and continuity of NVP use. 
 
 
Table 3-2 Effect of gender on duration of NVP therapy 
Group Male Female P value 
I 14 6 NS 
II 31 4 NS 
III 19 5 NS 
 
NS= Not Significant 
 
 
3.1.4 Effect of CD4 count  
Baseline CD4 was not significantly different between those continuing NVP at the time of 
study and those who had discontinued treatment (p=0.288). Non-parametric Mann-Whitney test 
was used since the data was skewed.  
 
When baseline CD4 counts of all the patients included in the study was compared with length 
of stay on NVP, no significant difference was observed (p=0.288). Individual CD4 counts of 
patients can be sighted from Table 3-3 and figure 3-2 represents the CD4 count vs. number of 
months in the study group. Non-parametric Mann-Whitney test was used since the data was 
skewed. The mean baseline CD4 values for groups I, II, III did not yield any significance 
differences. The average baseline CD4 was 437, 356.9, 352.4 respectively for groups I, II and 
III.  
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Figure 3-2 Baseline CD4 distribution 
 
Table 3-3 Baseline CD4 distribution 
CD4 Count < 6 months 6-60 months > 60 months 
 180 44 60 
 240 51 72 
 240 52 195 
 260 60 234 
 280 84 255 
 286 100 276 
 288 122 285 
 300 148 300 
 350 224 324 
 360 237 338 
 396 250 341 
 396 255 348 
 400 266 357 
 405 289 391 
 576 290 408 
 616 320 420 
 650 322 440 
 680 323 456 
 
756 342 528 
 
1081 364 549 
  396 594 
  437 612 
  456 675 
  462  
  475  
  476  
  486  
  531  
  576  
  620  
  640  
  644  
  672  
  696  
 
 780  
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3.1.5 Effect of baseline RNA 
Baseline RNA was not significantly different between those 2 groups (Yes, No) of continuing 
NVP use and those who had discontinued (p=0.872). Non-parametric Mann-Whitney test was 
used since the data was skewed.  Comparing baseline RNA and continuity of NVP did not 
result any significantly different results (p=0.872). Table 3-4 represents the individual RNA 
values of the patients in the study and figure 3-3 represents Baseline RNA vs. number of 
months on therapy. Non-parametric Mann-Whitney test was used since the data was skewed. 
The mean baseline RNA values in the three groups did not yield any significant difference. The 
average baseline RNA values for groups <6m, 6-60m and >60m therapy were 138489.21, 
149121.36 and 100538.56 respectively.  
 
 
 
Figure 3-3 Baseline RNA distribution 
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Table 3-4 Baseline RNA distribution 
HIV RNA < 6 months 6-60 months > 60 months 
 
17608 22754 104702 
 
81283 154882 12500 
 
17099 ND 82088 
 
19415 52000 218000 
 
15543 115343 31623 
 
66089 5536 410663 
 
39300 89300 28000 
 
85114 178178 5407 
 
660693 389045 117350 
 
33864 ND 64802 
 
115000 84812 4976 
 
155479 515355 462674 
 
75000 ND 9515 
 
161000 ND 208930 
 
100000 130000 17054 
 
219111 2130 21854 
 
ND 41800 ND 
 
39101 82823 110200 
 
11200 81283 123479 
 
719400 106000 34443 
 
 30700 157692 
 
 ND 47863 
 
 750000 7669 
 
 579225 30903 
 
 188000 
 
 
 118779 
 
 
 4900 
 
 
 30200 
 
 
 14125 
 
 
 100000 
 
 
 100000 
 
 
 93325 
 
 
 100000 
 
  
263027 
 
  
50119 
 
 
 
 
 
 
 
 
 
 
 
 59 
3.1.6 Effect of IL-1A 
There was no significant association between IL-1A genotype and continuing NVP use 
(p=0.931). Chi-squared test was used. When a Chi-squared (χ2) test was employed to identify 
any association between IL-1A and continuity of NVP, the result was found to be non 
significant (p= 0.931). Figure 3-4 represents number of patients vs. IL-1A and Table 3-5 
represents the distribution of the IL-1A in the three groups.  
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Figure 3-4 IL-1A genotype distribution 
 
 
Table 3-5  IL-1A genotype distribution 
IL-1A genotype < 6 months 6-60 months > 60 months 
1,1 10 19 14 
1,2 7 13 6 
2,2 2 1 2 
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3.1.7 Effect of IV drug use 
 
Upon observing the data collection sheet it is evident that only one patient from group I, three 
patients from group II and two patients from group III acquired HIV from mutual exchange of 
IV injections. However, taking the total population into consideration, the percentage of IV 
drug use was not significant.  
 
 
3.1.8 Effect of HLA 
 
The frequency of HLA alleles in different time groups can be observed from the following 
tables. 
 
Table 3-6 HLA- A  allele distribution 
HLA A gene 
allele 
0-6 months 
(n=22) 
6-60 months 
(n=29) 
60+ months 
(n=22) 
Control 
Frequency 
A1 27% 45% 18% 34% 
A2 32% 34% 55% 47% 
A3 18% 17% 27% 22% 
A11 18% 24% 18% 12% 
A23 5% 7% 0% 5% 
A9 0% 3% 0% NA 
A24 9% 21% 18% 22% 
A10 0% 0% 5% NA 
A25 0% 3% 5% 2% 
A26 5% 0% 0% 5% 
A29 14% 3% 5% 7% 
A30 9% 7% 5% 5% 
A31 0% 3% 5% 8% 
A32 27% 3% 9% 5% 
A33 5% 0% 0% 3% 
A34 5% 3% 0% 2% 
A36 5% 0% 0% 0% 
A68 5% 3% 0% 6% 
A69 0% 0% 0% 0% 
A74 5% 0% 0% 0% 
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NA- not available 
When a Chi squared analysis was performed comparing each individual HLA-A allele with the 
respective control frequency, the only significant association was for HLA-A 32 in 0-6 months 
group (27%) when   compared against Control frequency (5%) (p ≤ 0.001).  
Table 3-7 HLA-B  allele distribution 
HLA B gene 
allele 
<6 months 
(n=20) 
6-60 months 
(n=29) 
>60 months 
(n=22) 
Control 
Frequency 
B5 9% 0% 0% NA 
B7 4% 24% 35% 21% 
B8 18% 7% 13% 25% 
B13 9% 10% 9% 6% 
B14 9% 0% 17% 6% 
B15 0% 14% 9% 16% 
B16 0% 3% 0% NA 
B17 0% 10% 0% NA 
B18 5% 10% 9% 7% 
B27 9% 3% 13% 6% 
B35 18% 27% 9% 13% 
B37 0% 14% 0% 3% 
B38 0% 3% 4% 3% 
B39 5% 0% 4% 3% 
B40 9% 24% 9% 19% 
B41 0% 3% 9% 1% 
B42 5% 0% 0% 0% 
B44 14% 14% 17% 26% 
B45 0% 3% 0% 1% 
B49 5% 3% 17% 3% 
B50 5% 0% 0% 3% 
B51 14% 14% 4% 9% 
B52 9% 0% 4% 1% 
B53 0% 3% 0% 1% 
B56 9% 0% 0% 3% 
B57 5% 10% 13% 7% 
B58 5% 0% 0% 3% 
B35+CW4 18% 24% 0% NA 
NA- not available 
When a Chi squared analysis was performed for all the HLA-B gene alleles comparing their 
frequencies in the subgroups of patients with the respective control frequencies, most of alleles 
were found not to be significantly different in frequency.  However the frequencies of HLA-
B14 in the 60+ group (p < 0.05), HLA-B 37 in 6-60 months group (p < 0.01), HLA-B41 in 60+ 
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group (p < 0.01), HLA-B49 in 60+ group (p < 0.001) and HLA-B52 in the less than 6 months 
group (p < 0.01) were all significantly increased when compared with the respective control 
frequencies. 
Table 3-8 HLA-C  allele distribution 
HLA C gene 
allele 
<6 months 
(n=18) 
6-60 months 
(n=26) 
>60 months 
(n=22) 
Control 
Frequency 
Cw1 10% 8% 22% 3% 
Cw2 5% 11% 4% 8% 
Cw3 5% 31% 4% 32% 
Cw4 19% 38% 9% 17% 
Cw5 5% 4% 13% 18% 
Cw6 24% 31% 13% 17% 
Cw7 67% 35% 57% 52% 
Cw8 10% 4% 17% 7% 
Cw12 10% 4% 17% 10% 
Cw14 10% 0% 0% 1% 
Cw15 10% 11% 4% 6% 
Cw16 10% 4% 4% 12% 
Cw17 5% 8% 9% 2% 
 
 
The frequencies of HLA-CW3 in the <6 months (p < 0.025) and 60+ patient groups (p < 0.01) 
were significantly different from the frequency in controls. Interestingly the frequency of HLA 
CW3 in the 6-60 month patient group was identical to control.  By contrast the frequency of 
HLA –Cw4 in the 6-60 months group was significantly increased when compared to the control 
frequency (p < 0.01). HLA-CW17 in the 60+ group was also significantly increased when 
compared with its control frequency (p < 0.025).  
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Table 3-9 HLA-DRB1  allele distribution 
HLA DRB1 
gene allele 
<6 months 
(n=17) 
6-60 months 
(n=28) 
>60 months 
(n=21) 
Control 
Frequency 
DR1 14% 14% 13% 22% 
DR6 5% 3% 0% NA 
DR15 36% 21% 39% 21% 
DR16 5% 3% 0% 3% 
DR3 27% 18% 17% 23% 
DR4 9% 28% 26% 34% 
DR11 14% 18% 13% 17% 
DR12 0% 3% 9% 5% 
DR13 9% 10% 26% 22% 
DR14 9% 21% 0% 4% 
DR7 41% 21% 30% 30% 
DR8 14% 7% 4% 5% 
DR9 0% 7% 0% 5% 
DR10 5% 3% 0% 1% 
 
NA- not available 
 
 
There existed no significant relation between most HLA-DRB1 alleles and their respective 
control frequencies. The frequency of HLA-DR14 in the 6-60 months group was found to be 
significantly different from its control frequency when Chi-squared analysis was performed (p 
< 0.001).  
 
In contrast to earlier published data (Littera et al.) we found no association between the 
presence of HLA-DR1 or HLA-B14 and early withdrawal from NVP therapy (Tables 3.6 to 
3.9).  
 
 Since the 35.1 ancestral haplotype has previously been associated with AIDS progression the 
frequencies of the combination of HLA-B35 and HLA-CW4 (part of the 35.1 ancestral 
haplotype) in the patient groups and controls were compared with each other to determine any 
possible influence on the longevity of NVP therapy.  The combination HLA-B35+HLA-CW4 
did not occur in any of the NVP long term responders (NLTRs). This association between 
HLA-B35+HLA-CW4 and NLTRs was not described in previous studies. Furthermore, when a 
survival analysis was performed carriage of HLA-B35+HLA-CW4 identified patients who 
were not NLTRs. The median survival time for patients with HLA-B35+HLA-CW4 was 30 
months compared to 91 months with those without HLA B35+HLA-CW4. The survival 
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distributions were significantly different (p= 0.002). Survival analysis here means the time 
analysed till the cessation of NVP use. 
3.1.9 Survival Analysis 
 
A survival analysis of patients with HLA B35+CW4 compared with those not bearing this 
combination of HLA antigens is shown in figure 3-2. The data was depicted in two ways.  In 
the first all patients were included, even those whose duration of NVP therapy was shorter than 
60 months but were still on the drug (non-censored).  The second analysis made allowance for 
those patients who were still on NVP therapy but whose duration of therapy was less than 60 
months (censored).  The significant effect of HLAB35+CW4 on continuation of NVP therapy 
was clear no matter which analysis is considered. 
 
 
Figure 3-5 HLA- B35+HLAC4 Survival analysis 
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The median survival time for those with HLAB35+C45 is 30 months compared to those 
without: 91 months. 
 
 
Table 3-10 Overall comparisons of survival curve 
Test Chi-Square df Sig. 
Log Rank (Mantel-Cox) 9.987 1 0.002 
 
 
 
 
The survival distributions are significantly different (p=0.002), thus indicating that subjects 
without HLA-B35+HLA-CW4 combination used NVP for a significantly longer duration 
compared to those without the combination of genotype. However, study on a larger cohort and 
potentially including treatment-experienced patients may divulge more reasons for NVP 
discontinuation.  
 
3.1.10 Interpretation of survival curve 
The graph shows that the survivor function for group with HLA-B35+HLA-CW4 consistently 
lies above that of the group that lacks the allele combination. However, the two groups were 
somewhat closer in the first few months of follow-up, but thereafter are quite spread apart. This 
widening gap suggests that the people who discontinued from NVP therapy had HLA-
B35+HLA-CW4 combination and those without the allele combination continued therapy.  
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4 Discussion 
This study examined the characteristics of long term responders of Nevirapine therapy 
considering different factors such as age, gender, baseline CD4 T cell count, baseline RNA 
levels, IL-1A genotype, and various HLA alleles. The data for the study was obtained from the 
Department of Immunology, Royal Perth Hospital, Western Australia. Royal Perth Hospital is 
the state regional centre for HIV/AIDS diagnosis and treatment. The present study investigated 
whether or not all the above factors predicted the long term response to NVP therapy. The main 
objectives of the study were to define Nevirapine long term responders and identify the 
characteristics of patients who stay on the drug for long periods of time without adverse effects 
and maintain suppression of HIV replication without development of resistance. 
 
4.1 Significance of the study 
NVP is a very potent drug and was the first NNRTI available for the treatment of HIV 
infection. It is an extensively used ARV drug and is a crucial component of HAART126, 127. 
NVP can be used in treatment simplification strategies and also involved in the treatment of 
NVP naïve patients128-130 . Although the clinical results of Nevirapine therapy are promising 
there is still a concern about the high drop-out rate of patients from the therapy. Given the 
seriousness of this complication it is important to determine the most effective means of 
prevention of drop-out rates. Upon examining the patients genetic nature by evaluating the 
results from gene marker reports we may be able to predict whether the patient would adhere to 
the therapy or drop-out from the therapy.  
 
4.2 Incidence of Adherence to Nevirapine based on gender 
A research by Bersoff-Matcha et al124, demonstrated that females  had 7-fold increased risk of 
severe rash and were 3.5 times more likely to discontinue NVP therapy compared to men. 
Some people are intolerant to the adverse effects of the drug amongst which rash and liver 
toxicity are the major ones6. Nevirapine has an excellent safety profile and its penetration into 
CNS provides an option for patients with HIV associated dementia. But the severe adverse 
affects of NVP like hepatic toxicity, fever, oral lesions and ulcers and the most common 
treatment-limiting adverse effect rash restricted the universal use of the drug. The study by 
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Bersoff-Matcha et al started with the approach that female gender is more prone to acquire rash 
compared to males. The participants included in the study were ≥13 years of age who received 
ARV regimen with NVP as a component. The results in the study stated that severe rash 
occurred in 3.4% of the population. The risk of severe rash was 1.1% in men and 9.5% in 
females. The rate of discontinuation NVP was more among females (13.7%) compared to 
males (3%) due to occurrence of rash.  
However, in this research at RPH, when we tried to observe any association between gender 
and continuity with NVP using Chi-squared test, a P value of 0.165 was obtained showing that 
there was no significant relationship between gender and continuity with NVP. 
 
 
4.3 Incidence of adherence to Nevirapine based on CD4+T cell count and baseline 
RNA levels 
 
 A study  performed by  Sanne et al  claimed that female patients with CD4+ T cell count > 250 
cells/mm3 and male patients with CD4+T cell count > 400 cells/mm3 are more susceptible to 
get liver toxicity and are likely to discontinue NVP therapy110. The study recruited HIV-1 
infected non-pregnant women and men in South Africa with plasma RNA levels >5000 
copies/ml and CD4+ T cells/mm3, all of whom were ARV therapy naïve. The patient population 
who met the inclusion criteria was 468 who were enrolled between August 1999 and February 
2000. 385 patients (82%) were administered NVP as part of their ARV regimen. 17% of the 
patients who received NVP acquired hepatotoxicity , 12.8% in men and 20.1% in women. The 
onset of hepatotoxic events started within 12 weeks of the start of NVP therapy in 80% of the 
patients who received NVP. In accord with other studies the study by Sanne et al confirmed 
that women with CD4+T cell count >250 cells/mm3 and men with CD4+ T cell count >400 
cells/mm3 hepatotoxic events compared to those with lesser CD4 counts. The reason for this 
was attributed to low BMI (<18.5) for females due to low nutritional status.  
 In contrast to the previous studies, in our study none of the factors either, age, sex, baseline 
CD4+ T cell count, baseline viral RNA count seemed to influence long term use of NVP. 
Results from the study indicated that there was no significant difference between patient 
demographics between each of the three groups.  
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 A study by Martin et al131  attempted to establish a relation between NVP hypersensitivity and 
presence of HLA DR1 and CD4 status. Before start of their study, they predicted that there 
could be an association between HLA markers in class II region of the MHC and low CD4+ T 
cell counts and occurrence of NVP hypersensitivity. The study was started with the belief that 
MHC class II limits the CD4+ T cell mediated immune responses directed against drug specific 
antigens which inturn might be responsible for drug hypersensitivity. A total 235 patients who 
received NVP for more than 6 weeks without symptoms or who developed NVP induced 
reactions were included in the study. HLA typing was performed at HLA-DR, HLA-DQ, HLA-
A, HLA-B and HLA-C loci at enrolment. Upon analysis it was revealed that threat of hepatic 
toxicity reactions due to NVP was most significantly associated with interaction between 
presence of HLA-DR1 and high CD4+ T cell count. The rate of occurrence of NVP toxicity 
was similar in those with low CD4+ T cell count and those with high CD4+ T cell count but 
who lacked HLA-DR1. Conversely, presence of HLA-DR1 and highCD4+ T cell count was 
associated with higher risk of NVP toxicity.  
 
On comparing the results of the above study with our research, there was no such relation 
between HLA-DR1 and CD4+ T cell count and NVP toxicity which inturn reflects in adherence 
to NVP therapy.  
 
 
A study by Littera 132 stated that a combination of HLA-B14 and HLA-C8 may determine the 
susceptibility to NVP hypersensitivity. They predicted that NVP toxicity is not either due to 
NVP dose or due to an association with cytochrome P450 enzyme.  NVP toxicity could be due 
to a hypersensitive reaction in which NVP or its glucuronide metabolites act as specific 
antigens which elicit a T-cell mediated immune response in genetically susceptible individuals. 
Based on these principles they hypothesised that hypersensitivity reaction due to NVP may be 
HLA associated. A total of 49 HIV-1 positive patients were enrolled for the study. Before start 
of therapy all the patients were subjected to tests to determine the levels of liver enzymes, 
screening for hepatitis C virus antibodies and hepatitis B virus surface antigens. Levels of 
CD4+ T cell and CD8+ T Cells were also determined. The results demonstrated that 13 of the 
49 patients developed hypersensitivity to NVP within 3-60 days of start of NVP therapy. HLA 
typing showed that six of the thirteen patients (48%) had HLA-B14, HLA-C8 antigens. The 
results proved the hypothesis acceptable where patients with HLA-B14 and HLA-C8 
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combination would develop hypersensitivity with NVP therapy. Thus the authors confirmed the 
role of HLA molecules in NVP hypersensitivity.  
 
Upon comparing our study results with the study mentioned above, no correlation between 
HLA-B14 and HLA-C8 combination and continuity with NVP was demonstrated. 
 
Immunologists at RPH headed by Patricia Price12 performed study that tried to investigate 
whether polymorphisms in cytokine genes affected the control of HIV RNA for people 
receiving HAART over five years. They tried to throw light on the association between 
virological failure and polymorphisms in genes encoding pro-inflammatory cytokines. All the 
patients included in the study were  recent cases who were detected HIV positive with low 
CD4+ T cell counts of <100cells/µl. A total of 81 patients met with the inclusion criteria and 
were placed on ARVs using a combination of a protease inhibitor, NRTI and NNRTI. IL1A-
889 and IL1A+4985 alleles were assessed using restriction fragment length polymorphism 
(RFLP). The results state that carriage of allele 2 at position -889 in the IL1A gene could 
predict the control of viraemia for patients who are immunodeficient (low CD4+ T cell count) 
and  responding to HAART. The same results were observed for polymorphisms at IL1A+4845 
and thus in concordance with the predictions of IL1A-889. In conclusion they declared that 
alleles IL1A-889 or IL1A+4845 may expect to control of HIV replication in patients with a low 
CD4+ T cell who respond commendably with HAART. 
 
When a comparison was made with the above study with our research, IL1A (1,1), (1,2) and 
(2,2) ; no significant relation between  IL1A and continuity with NVP were observed (p= 
0.931).  
 
Upon performing a survival analysis for length of time on NVP and using presence or absence 
of HLA-B35+HLA-CW4 alleles as criteria, we did find that NLTRs never had the HLA-
B35+HLA-C4 antigen combination. Thus, this finding suggests that carriage of these genes is a 
risk factor for toxicity or early development of NVP resistance.  These two HLA antigens form 
part of the 35.1 and 35.2 ancestral haplotypes which have previously been associated with rapid 
progression to AIDS in patients infected with HIV (Flores- Villaneuva et al, 2003)133.  Both 
HLA B35 and CW4 were present in some patients in the NLTR group so that it is unlikely that 
these alleles by themselves confer susceptibility to adverse reaction to NVP.   Interestingly, 
neither DR11 nor DR1, which are present on the 35.1 and 35.2 haplotype, were not associated 
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with early withdrawal of NVP in this study.  Whether the association of the 35.1 and 35.2 
ancestral hapotypes with disease progression is relevant to the observation in this thesis is 
unclear, although the presence of this haplotype, or at least genes within that haplotype, may 
contribute to more severe disease by affecting both disease progression and continuity of 
treatment with one potentially valuable anti-retroviral drug 
 
We stated in the hypothesis that the factors considered for the study may direct us towards 
preventing NVP induced toxicities to patients. In accordance with the hypothesis the study 
proclaims that those patients with a combination of HLA-B35+HLA-CW4 should not be 
administered NVP, though more information needs to be obtained as to why patients 
discontinued the therapy since complete information not available at the time of data collection. 
However, for those patients without the HLA-B35+HLA-CW4 allele can be recommended 
NVP therapy, for such patients NVP can be advised as part of the first regimen for HAART or 
NVP can be introduced if any of the previously used ARV drugs proved ineffective.  
 
A number of other HLA-A, HLA-B and HLA-C antigens were increased in frequency in 
certain subgroups of patients compared to other subgroups and controls.  Although, these 
analyses were not subject to Bonferroni correction, so that some of the weaker associations 
may have been demonstrated by chance alone, these observations might suggest that other 
ancestral haplotypes or at least HLA antigens could be implicated in the response to NVP.  
Clarification of this issue will require more detailed study of a larger group of patients and to 
explore reasons to ceasing the drug. 
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5 Conclusion and Future Studies 
In conclusion it can be stated that various demographic and genetic factors considered for 
determination of NVP long-term response could not foretell the reasons for the high drop-out 
rate from NVP therapy. However, this study found that HIV patients with HLA-B35+HLA-
CW4 antigen were prone to discontinue NVP. Further studies need to be undertaken to 
determine the reasons for this.  
 
A comparison of these study results with studies in the same setup with a larger population 
would consolidate the results of this study. Further analyses of the frequency of HLA-
B35+HLA-CW4 antigen in patients who developed hypersensitivity reaction to NVP (skin 
rashes and liver toxicity) is warranted. It would be helpful if studies involving other 
combinations of HLA antigens are studied for the betterment in the advancement of HIV 
medicine and care to HIV patients. 
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7 Appendix 
Presentation 
To determine the characteristics of HIV patients who are Nevirapine Long-term responders 
Vijay Tenneti1, Prof. Michael Garlepp1, Dr. Martyn A French2 and Steven Roberts2 
1
 School of Pharmacy, Curtin University of Technology, WA; 
2
 PathWest Immunology, Royal Perth Hospital and School of Surgery and Pathology, 
University of Western Australia; 
This study was presented at the following conference: 
Australian Pharmaceutical Science Association, Adelaide, Australia, 2-5th Dec 2006. 
Objective: The objective of the research is to define Nevirapine long term responders (NLTRs) 
and identify the characteristics of patients who stay on the drug for long periods of time without 
adverse effects and maintain suppression of HIV replication without development of resistance. 
Methodology: The patient population was divided into three groups based on their length of 
stay on Nevirapine; short-term, medium and long-term responders.  Patients who stayed on 
Nevirapine continuously for more than five years were considered long-term responders. 
Patients who withdraw before six months of therapy due to the drug’s side effects or any other 
reason are considered short-term responders. Patients whose length of stay on the drug is 
intermediate between these two groups are considered as medium responders. There were 
almost 500 cases of HIV in the hospital during the period of study. But patients to whom NVP 
was given as the first drug for treatment were taken into the study; hence the patient population 
in the study was only 79. Investigation of the possible genetic influence on response to Nevirapine 
was made by use of genetic markers like HLA-B35+C4, HLA-DR1, and HLA-B14. 
Results: We found no difference in the frequencies of HLA-DR1 or HLA- B14 in the three 
groups. However, we found that HLA-B35+C4 did not occur in any of the NVP long term 
responders (NLTRs), which was not described in previous studies. Furthurmore, when a 
survival analysis was performed, carriage of HLA-B35+C4 identified patients who were not 
NLTRs. The median survival time for patients with HLA B35+C4 was 30 months compared to 
91 months with those without HLA B35+C4. The survival distributions were significantly 
different (p= 0.002). 
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Conclusions: Although, the factors are considered for the study are associated with hyper-
sensitivity reactions, they do not predict how long a patient would stay on the drug. There was 
no significant relationship between gender, age, duration of Nevarapine use and whether or not 
the patient was continuing Nevarapine. 
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